The CEOs from NPS Pharma, Onyx Pharma, Bristol-Myers Squibb, Celgene and Ligand Pharma vie for the coveted title of Best Biotech CEO.
Leukemia and Lymphoma Society has asked Stemline to stop using cancer patient testimonials in its investor presentations.
The cash will paid to top execs if Amarin can win an expansion of its fish-oil pill.
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.
After a red-hot start, biotech IPOs are now underperforming the broader market.
Orexigen Therapeutics is the best-performing obesity drug stock of 2013, topping rivals Vivus and Arena Pharma.
Optina's 505(b)(2) filing strategy appears to be running into trouble with the FDA, according to Ampio's SEC filings.
Contrave will be resubmitted for FDA approval "within a few weeks," Orexigen said.
Biogen Idec and Gilead Sciences are helping the biotech sector recover from a sloppy fourth quarter performance.